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d applicAbstract Carteolol (CRT) is currently under development as a potential therapeutic agent for the
treatment of open angle glaucoma. The purpose of the present work is to develop and validate a sta-
bility indicating assay method and its application to estimate CRT in aqueous humour and study the
pharmacokinetic parameters. An ultra performance liquid chromatographic tandem mass spectroscopy
(UPLC–MS/MS) method was developed and validated for the quantitative determination of CRT in
rabbit aqueous humour, using propranolol as the internal standard (I.S.). Aqueous humour samples
were prepared by a simple liquid–liquid extraction technique (LLE). The analyte and internal standard
were separated by an Acquity UPLC BEH C18 (100.0 · 2.1 mm; 1.7 lm) column with a mobile phase
of acetonitrile – 2 mM (milli mole) ammonium acetate (90/10, v/v) over 3 min of retention time. Detec-
tion was based on the multiple reactions monitoring with the precursor-to-product ion transitions m/z
293.2ﬁ 237.12 for CRT and m/z 260.09ﬁ 183.04 for I.S. The method was validated according to
FDA guidelines on the bio-analytical method validation. The method developed was linear
(r2 = 0.999) over the concentration range of 1–1000 ng/mL. The selectivity, sensitivity, linearity, accu-
racy, precision, extraction recovery, and stability were within the acceptable ranges. Forced degradation
studies were performed on bulk sample of CRT as per ICH prescribed stress conditions, such as acid,
base, oxidative and photolytic to show the forced of the method. Signiﬁcant degradation was observed
during basic stress condition. The pharmacokinetic study of CRT solution and nanoparticles in aque-
ous humour of rabbit eye was performed and results showed that CRT nanoparticles enhance the ocu-
lar bioavailability by 5.61-fold as compared to CRT-solution.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.9899571726.
(A. Ali).
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2 Ameeduzzafar et al.1. Introduction
Glaucoma is a group of diseases characterised by a progressive
form of optic nerve damage associated with raised
(>21 mmHg) intraocular tension (i.o.t) and reduction of the
visual ﬁeld. Many of drugs, including b-adrenergic blocking
agents (b-blockers oral and eye drops), have been topically ap-
plied to lower intraocular pressure (IOP). Some of them have
been prescribed concomitantly with the other antiglaucoma
drugs, such as prostaglandins, acting by different mechanism
in order to cause synergism (Zimmerman, 1993; Novack
et al., 2002; Ohtake et al., 2004; De Santis, 1994). In spite of
the wide use for glaucoma therapy, it is well known that top-
ically administered b-blockers may cause severe cardiovascular
side-effects, and nonselective b-blockers may cause respiratory
failure (Shields, 1992). CRT is the second most commonly pre-
scribed topical b-blocker in the world with intrinsic sympat-
homimetic activity and exert a partial agonism at the
adrenergic receptor while simultaneously block natural endog-
enous agonist from binding to the receptor. This activity has
proved effective in a real reduction of some side effects (Black
and Mann, 1984; Moroi and Lichter, 2001; Nathanson, 1980).
The chemical name of CRT is (±)-5-[3-[(1,1-dimethylethyl)
amino]-2 hydroxypropoxy]-3,4-dihydro-2(1H)-quinolinone
(Fig. 1A), available as 1–2% w/v aqueous eye drop solution,
(Kuwahara et al., 2005; Trinquand et al., 2003). Almost all
drugs administered as eye drops are drained from the precor-
neal area into the systemic circulation by the way of the naso-
lacrimal duct. Therefore the ocular bioavailability of drugs
instilled is often very low, typically 1% or less (Jarvinen
et al., 2000). This is one of the reasons causing such adverse
effects of ophthalmic drugs. Various novel drug delivery sys-
tems such as in situ gelling system (El-Kamel et al., 2006),
ion transport system (Higashiyama et al., 2006) and algenic
acid (Se´choy et al., 2000) delivery have been investigated by
many researchers in an effort to overcome poor bioavailability
of CRT after topical application. So advantages of these novel
formulations include prolonged pre-corneal retention and re-
duce the systemic side effect, which, in turn, is good for the
quality of life of patients.
Quantiﬁcation of CRT in biological ﬂuid by chromato-
graphic procedures like mass spectrometry (Zammataro
et al., 2010) and HPLC (El-Kamel et al., 2006) has been re-
ported previously. Quantiﬁcation of CRT concentration in
aqueous humour is described in the literature by HPLC
(Zammataro et al., 2010). The combination of HPLC with
the tandem mass spectrometer (MS/MS) has become more
and more attractive for the quantiﬁcation of drugs at low levelFigure 1 Chemical structure of Carteolol (A) and propranolol
(B).
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been used to quantify CRT and dorzolamide simultaneously
(Zammataro et al., 2010). As Compared to conventional
HPLC analysis, ultra performance liquid chromatography
(UPLC) performed with Acquity BEH 1.7 lm columns can
provide greater peak capacity, higher speed and efﬁciency
(De Villiers et al., 2006). Moreover, in comparison with
HPLC–MS/MS, UPLC is a new chromatographic technique
utilising high linear velocities, which is based on concept using
columns with smaller packing (1.7–1.8 lm porous particles)
and operated under high pressure (up to 15,000 psi). This is
an extremely powerful approach which dramatically improves
peak resolution, sensitivity and speed of analysis. In addition,
time of-ﬂight mass spectrometry (Q-TOF-MS) allows the gen-
eration of mass information with higher accuracy and preci-
sion. UPLC is specially designed to resist higher back-
pressures, with the advantages of fast injection cycles, low
injection volumes, negligible carryover and temperature con-
trol (4–40 C), which collectively contribute to speedy and sen-
sitive analysis. The UPLC–MS/MS technique produces
signiﬁcant improvements in method sensitivity, speed, and res-
olution (Abdelbary and Nebsen, 2013; Churchwell et al., 2005;
Du et al., 2013; Gupta et al., 2013; Mazzarino et al., 2008;
Nzoughet et al., 2013; Pedraglio et al., 2007; Tho¨ngren et al.,
2008; Wilson et al., 2005). Therefore, in this study, we developed
a rapid, sensitive and selective UPLC–MS/MS method to quan-
tify CRT in small volumes of aqueous humour and also do stress
study the samples as per ICH guidelines (ICH. Topic Q2-R1,
2005). Liquid–liquid phase extraction was chosen to extract
CRT from aqueous humour samples which resulted in good
recovery, lack of endogenous interference, and moderate matrix
effect. The proposed UPLC–MS/MS method with simple pre-
treatment procedures was successfully applied to assess the phar-
macokinetic proﬁles of CRT- solution and CRT nanoparticle
formulation in aqueous humour of rabbit’s eye.
2. Experimental
2.1. Chemicals and reagents
CRT (purity: 99.98%) was a kind gift from Otsuka Pharma-
ceutical Co., Ltd, Japan. Chitosan (CS, deacetylation degree
>85%) was received as a gift sample from India Sea Foods
(Kerala, India). Acetonitrile and methanol were obtained from
SD Fine (Mumbai, India). Ammonium acetate (**LCMS
grade), formic acid (LCMS grade), ammonium format and
ethyl acetate were obtained from SD Fine (Mumbai, India).
All solvents and reagents were of analytical reagent grade. Ul-
tra-pure water was produced by a Milli Q (Millipore, Billerica,
MA, USA) system. Eppendorf tubes (1–2 mL) were used to
store solution during the preparation of the standard solution
and aqueous humour samples.
2.2. Liquid chromatography
UPLC analysis of CRT in aqueous humour was performed on
a Waters ACQUITY UPLC system (Waters Corp., MA, USA)
equipped with a binary solvent delivery system, an auto-sam-
pler, column manager and a tunable synapt MS detector (Syn-
apt; Waters, UK). UPLC Chromatographic separation was
performed on a Waters Acquity UPLC BEH C18 columnalidation of UPLC/ESI-Q-TOF-MS for carteolol in aqueous humour:
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umn (5 · 2.1 mm, 1.7 lm particle size) waters acquity. The mo-
bile phase consisted of acetonitrile: 2 mmol ammonium acetate
buffer (90:10, v/v) at column temperature of 40 C, auto sam-
pler temperature at 4 C and ﬂow rate of 0.2 mL/min. The
injection volume was 10 ll in full loop mode. Retention time
was 1.29 min and total chromatographic run time was 3.0 min.
2.3. Mass spectrometry
Synapt-mass-spectrometric detection was carried out on a
UPLC–MS/MS (Q-TOF-ESI) (Waters Corp., USA) with an
electrospray-ionisation (ESI) technique. The ESI source was
used in positive ionisation mode. Quantiﬁcation was per-
formed using synapt MS (Q-TOF) of the transitions of m/z
283.2ﬁ 237.12 for CRT and m/z 260.09ﬁ 183.04 for IS, with
scan time of 1.0 min per transition and internal scan time was
0.05 s. Microchannel plate (MCP) was used as a detector plate.
The optimal MS parameters are as follows: capillary voltage
3.60 kV, cone voltage 21 V, extraction cone voltage 7.40 V,
source temperature 120 C, desolvation temperature, 350 C;
cone gas ﬂow, 50 l/h; desolvation gas ﬂow, 500 l/h; and colli-
sion energy was 16.5. Nitrogen was used as the desolvation
and cone gas. Argon was used as the collision gas at ﬂow of
1.5 mL/min. All data collected in centroid mode were acquired
and processed using MassLynx V 4.1 software.
2.4. Standard solutions, spiked samples and quality control
(QC) sample preparation
The standard stock solutions of CRT analyte and propranolol
internal standard were prepared at 1000 lg/mL in methanol.
With that solution a working solution containing the adequate
concentrations of all the analytes was prepared in methanol:
water (50:50) to spike the aqueous humour samples covering
the linearity range (1–1000 ng/mL). A 100 ng/mL solution con-
taining the IS propranolol was also prepared in methanol and
diluted with methanol: water (50:50).
Calibration standard was prepared by spiking a pool of
drug free aqueous humour (50 lL for each concentration) with
the working standard solution and it was diluted to desire con-
centration range from 1 to 1000 ng/mL. The ﬁnal concentra-
tion for each analyte was prepared to be **1.010, 2.900,
22.136, 208.378, 420.378, 638.000, 850.000, and 1000.000 ng/
mL. Calibration standards were processed according to the
sample preparation procedure and analysed by the UPLC–
MS/MS method. QC samples were prepared independently
at three levels; **800.000 ng/mL (HQC, high quality control),
400.000 ng/mL (M2QC, middle quality control), 34.059 ng/
mL (M1QC, middle quality control) and 2.900 ng/mL (LQC,
low quality control) and 1.010 ng/mL (LLQC).
2.5. Sample treatment
A volume of 50 lL aliquot of all rabbit aqueous humour was
pipetted into a 1.5 mL eppendorf tube and spiked with 50 lL
of a 100 ng/mL IS solution propranolol. Protein precipitation
was carried out using 200 lL formic acid (2% v/v) solutions.
After vortex mixing, it was transferred to a 5 mL glass vial
and 3 mL of ethyl acetate was added, shaken and centrifuged
at 18,000 rpm for 10 min. The supernatant was transferred toPlease cite this article in press as: Ameeduzzafar, et al., Development and v
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stream at 60 C. The residue was reconstituted with 500 ll of
mobile phase (acetonitrile: 2 mM ammonium acetate 90:10 v/
v) and vortexed. The solution was transferred into the clean
auto sampler vials and 10 lL was injected into UPLC/MS sys-
tem for analysis. All the aqueous humour of rabbit samples
were stored at 20 C, allowed to thaw at room temperature
and were vortexed for 5 min prior to sample preparation.
2.6. Method validation
The method was validated according to internationally ac-
cepted recommendations (US Food and Drug Administration,
2012). The method was validated in terms of linearity, preci-
sion, accuracy, extraction recovery, matrix effect and stability.
2.6.1. Speciﬁcity
The selectivity of the method was evaluated by comparing the
chromatograms of six different batches of blank aqueous hu-
mour with the corresponding spiked plasma (LLQC samples)
to ensure no interfering peak of analyte and I.S. from endog-
enous aqueous humour components.
2.6.2. Linearity and sensitivity
The calibration standards of concentrations 1.010, 2.900,
22.136, 208.378, 420.378, 638.000, 850.000, and 1000.000 ng/
mL were used to assess linearity, which were prepared accord-
ing to Section 2.4. Calibration curves were plotted as the peak
area ratio (drug/internal standard) versus the analyte concen-
tration. Least-squares linear regression method was used to
determine the slope, intercept and correlation coefﬁcient.
2.6.3. Accuracy and precision
The precision and accuracy of this analytical method were
evaluated by assay QC samples at 5 levels (LOQC, LQC,
M1QC, M2QC and HQC concentrations). The QC samples
were analysed six times a day to evaluate intra-day precision
and accuracy. The same procedure was performed once a
day for three consecutive days to determine inter-day precision
and accuracy. The accuracy and precision were calculated
using the formula published elsewhere (Lakhani et al., 2005)
and the criteria for acceptability of the data included accuracy
within ±15% standard deviation (SD) from the nominal val-
ues and precision within ±15% relative standard deviation
(RSD) (Bioanalytical Method Validation, US Department of
Health and Human Services Food and Drug Administration,
Center for Drug Evaluation and Research (CDER) 2001)
(Guidance for Industry, 2001).
2.6.4. Extraction recovery and matrix effect
The extraction recovery of CRT through the liquid–liquid
extraction method was evaluated at four QC concentrations:
2.900 (LQC), 34.059 (M1QC), 400.000 (M2QC) and 800.000
(HQC) ng/mL (n= 6). Extraction recovery was determined
by comparing the peak areas obtained from blank aqueous hu-
mour spiked with analyte before the extraction with those
from samples to which analyte was added after the extraction.
Matrix effect was assayed to compare the peak areas of blank
aqueous humour extracts spiked with analyte with those of the
standard solutions dried and reconstituted with mobile phase.alidation of UPLC/ESI-Q-TOF-MS for carteolol in aqueous humour:
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The stability study was performed to evaluate the stability of
the analyte in rabbit aqueous humour under the following con-
ditions: short-term stability at room temperature for 24 h;
long-term stability at 80 C for 30 days, freeze thaw (three
cycle at 20–25 C) cycles for three consecutive days and post
preparative stability of the processed samples kept under the
auto sampler conditions (10 C) for 24 h. All stability testings
in aqueous humour were performed at the LQC and HQC con-
centrations (n= 6). All samples were compared with regularly
analysed samples with the same amount of analyte and per-
centage stability was determined by the following formula. Sta-
bility was determined by statistical comparison of the
calculated concentrations (t-test, 95% signiﬁcance level).
%Stability ¼Mean response of stability sample
Mean response of 0h sample
 100 ð1Þ2.7. Forced degradation of CRT
A stock solution containing 50 mg CRT in 50 mL methanol
was prepared. This solution was used for forced degradation.
2.7.1. Preparation of acid- and base-induced degradation
product
To the volume of 20 mL of methanolic stock solution, 5 mL of
5 N HCl and 5 mL of 5 N NaOH were added separately. These
mixtures were reﬂuxed for 6 h at 90 C. The forced degradation
in acidic and basic media was performed in the dark in order to
exclude the possible degradative effect of light. The resultant
solution (400 ng/mL) was injected to UPLC–MS/MS system.
2.7.2. Preparation of hydrogen peroxide-induced degradation
product
To the volume of 20 mL of methanolic stock solution, 5 mL of
hydrogen peroxide (30.0%, v/v) was added. The solution was
heated in boiling water bath for 6 h to remove completely
the excess of hydrogen peroxide. The resultant solution
(400 ng/mL) was injected to UPLC–MS/MS system.
2.7.3. Photochemical degradation product
The photochemical stability of the drug was also studied by
exposing the stock solution to direct sunlight for 24 h. The
resultant solutions were appropriately diluted and 400 ng/mL
was injected to UPLC–MS/MS system.
2.8. Application of the developed method for pharmacokinetic
studies in ocular delivery of CRT
2.8.1. Preparation of CRT nanoparticles and characterisations
Chitosan (CS) nanoparticles were prepared according to the
procedure ﬁrst reported by Calvo et al. based on the ionic gela-
tion of CS with sodium tripolyphosphate (TPP) anions (Calvo
et al., 1997b). Chitosan was dissolved in 1% acetic aqueous
solution at various concentrations (0.05–0.30%). 4 mL TPP
aqueous solution with various concentrations (0.05% to
0.30%) was added into 10 mL chitosan solution, under mag-
netic stirrer at 1000 rpm for 45 min and the formation of chito-
san–TPP nanoparticles started spontaneously via the TPP
initiated ionic crosslink and coacervation mechanism. ThePlease cite this article in press as: Ameeduzzafar, et al., Development and v
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ratios of 2.5:1. CRT nanoparticles were collected by centrifu-
gation (15,000 rpm, 30 min), washed 3 times with Milli-Q
water, ﬁnally resuspended in 4 mL of Milli-Q water and dried
in a lyophilizer (Heto Drywinner, Germany).
2.8.2. Characterisation of chitosan nanoparticles
Chitosan nanoparticles were characterised for particle size,
particle size distribution zeta potential, polydispersity index
(size distribution) and morphology (Zetasizer 3000-HS Mal-
vern Instruments, UK) was used for measurement of particle
size, particle size distribution, zeta potential and polydispersity
index which is based on the Photon Correlation Spectroscopy
(PCS) techniques. Samples were diluted to appropriate concen-
trations with deionised water. Triplicate samples were analysed
and the mean value of the three was adopted. Morphological
characteristics of the nanoparticles were examined using a high
resolution Transmission Electron Microscope (TEM) machine
(Philips CM 10, Holland) at an accelerating voltage of 100 kV.
Data acquisition was done on the AMT Image Capture En-
gine. Freshly made nanoparticles were diluted with deionised
water with adjusted pH close to neutral. One-drop sample
was syringe placed on a carbon coated ﬁlm 300 mesh copper
grid, allowing sitting for 10 min until air-dried. The sample
was stained with 1% phosphotungstic acid solution for
1.5 min and excess phosphotungstic acid was removed with ﬁl-
ter paper before viewing for TEM.
2.8.3. Ocular Pharmacokinetic Study
The ocular pharmacokinetic study was performed on two
groups of New Zealand albino rabbits (n= 6) V and the study
was conducted as per the protocol and guidelines approved by
the institutional animal ethics committee, Jamia Hamdard (ap-
proval No. 771). For the topical instillation, weighed amount
of lyophilized CRT laden nanoparticles was dispersed in iso-
tonic buffer to get 1%w/v solution. CRT solution (1%, w/v)
was also prepared in the same vehicle. To the ﬁrst group,
CRT solution (50 lL) was instilled topically whereas to the
second group CRT-nanoparticles (50 lL) were instilled. For-
mulations were instilled in both the eyes of rabbits and approx-
imately 50 lL of aqueous humour was collected before
instillation of formulations and post-treatment at 0.5, 1, 2, 4,
6, 12 and 24 h from one rabbit (both eyes) at each time point.
Aqueous humour samples were collected in eppendorf tubes,
sealed and stored at 20 C until UPLC–MS/MS analysis.
The aqueous humour samples were prepared as mentioned
above. Pharmacokinetic parameters were calculated by non-
compartmental analysis, also called as model-independent
analysis using WinNonLin version 4.0 (Pharsight Corp.,
Mountain View, CA). Peak aqueous humour concentration
(Cmax) and time of its occurrence (tmax) were read directly from
the individual aqueous humour concentration–time proﬁles.
Area under the concentration–time curve (AUC 0t) was calcu-
lated according to the linear trapezoidal method.
3. Results and discussion
3.1. Optimisation of the UPLC/MS/MS method
A novel UPLC–MS/MS method was developed by using the
different compositions of mobile phase, which affected the sep-alidation of UPLC/ESI-Q-TOF-MS for carteolol in aqueous humour:
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various mobile phases such as methanol, isopropanol were
tried, but they did not show the chromatographic separation.
Therefore, the optimisation of mobile phase components was
critical. Various mobile phase composition such as methanol:
water, methanol: formic acid (0.1%), methanol: 1, 2, 5 mM
ammonium formate, acetonitrile: water, acetonitrile: formic
acid (0.1%) and acetonitrile: 1, 2, 5 mM ammonium formate
were tried but peak did not separate properly. Finally the opti-
mised chromatographic separation of CRT, was achieved by
using acetonitrile: 2 mM ammonium acetate buffer (90: 10,
v/v), with a ﬂow rate of 0.2 mL/min. Baseline separation of
both CRT and IS was obtained within runtime of 3 min and
fragments of high intensities were selected for ion monitoring.
The full MS scan spectra for CRT showed protonated precur-
sor [M+H]+ ions at m/z 293.18 and their product ion mass
spectra (MS/MS) at m/z 237.1 respectively neutral loss of iso-
buthene from the [M+H]+ of CRT, which was selected for
sensitive quantiﬁcation of the drug (Figs. 2 and Fig. 1C) while
I.S. response was showed at m/z 260.09 was which corresponds
to the respective protonated molecular ions [M+H]+ with
most abundant product ion (MS/MS) at m/z 183.04
(Figs. 2B and D). The retention times were 1.29 min for
CRT and 2.38 min for I.S respectively and total chromato-
graphic runtime was 3.0 min (Fig. 3A and B). Chromatogram
of blank plasma (extracted and reconstituted) is shown in
Fig. 3C.Figure 2 Full scan product ion mass spectra of the [M+H]+ at m/z
ion at m/z 237.13 (CRT) (C) and product ion at m/z 183.04 (Propran
Please cite this article in press as: Ameeduzzafar, et al., Development and v
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3.2.1. Speciﬁcity
The selectivity was evaluated by comparing the chromato-
grams of blank aqueous humour, and spiked aqueous humour
samples (LLOQ, 1.010 ng/mL) in pharmacokinetic studies.
Comparison of spiked aqueous humour samples and blank
aqueous humour showed no signiﬁcant peaks interfering with
the quantiﬁcation of the analyte and I.S. and the representative
chromatogram of aqueous humour samples showed similar
chromatographic behaviour to QCs.
3.2.2. Linearity and sensitivity
The calibration curve was linear with regression correlation
coefﬁcients (r2 = 0.999) over the concentration range of
1.010–1000 ng/mL. The equation of the calibration curves
was: y= 0.041x+ 0.238, r2 = 0.999 where x represents the
aqueous humour concentration of CRT and y is the peak area
ratio of CRT to I.S. The limit of quantiﬁcation (LOQ) was
found to be 0.75 ng/mL in aqueous humour (S/NP 10), which
was sufﬁcient to support pharmacokinetic studies of CRT. The
accuracy of the diluted samples of CRT was 99.38 ± 1.96 % at
400 ng/mL and 99.12 ± 2.01% at 800 ng/mL. The precision
determined at each concentration level was within 5% of the
relative standard deviation (%R.S.D.). The LOD and LOQ
were determined as 0.25 and 0.75 ng/mL respectively for
CRT in aqueous humour. Dilution study found that the assay293.18 (CRT) in the (A), m/z 260.09 (Propranolol IS) (B), product
olol IS) (D).
alidation of UPLC/ESI-Q-TOF-MS for carteolol in aqueous humour:
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Figure 3 Representative MRM chromatograms of: (A) Spiked CRT; (B) IS (100 ng/mL) and I.S.; and (C) blank aqeouse humour. The
m/z 293.18 > 237.13 transition was monitored for CRT and the m/z 260.09 > 183.04 transition for Propanolol (IS).
Table 1 Precision and accuracy of carteolol in aqueous humour (n= 6).
Conc.
(ng/ml)
Measured conc.
(Mean ± SD)
(ng/mL)
Intra-day Precision
(% RSD)
Accuracy
(Mean ± SD, %)
Measured Conc.
(Mean ± SD)
(ng/mL)
Inter day
Precision
(% RSD)
Accuracy
(Mean ± SD, %)
1.010 (LOQQC) 0.96 ± 0.02 1.53 95.05 ± 1.98 0.97 ± .01 1.05 96.04 ± 0.99
2.900 (LQC) 2.92 ± 0.10 3.82 100.68 ± 3.45 2.83 ± 0.12 4.24 97.59 ± 4.13
34.059 (M1QC) 32.17 ± 1.26 4.19 94.45 ± 3.70 32.74 ± 1.55 4.73 96.13 ± 4.35
400.000 (M2QC) 397.50 ± 7.82 1.97 99.38 ± 1.96 398.26 ± 7.53 1.98 99.57 ± 1.88
800.000 (HQC) 795.49 ± 12.71 1.60 98.81 ± 2.34 792.94 ± 16.08 2.03 99.12 ± 2.01
RSD (%): relative standard deviation.
6 Ameeduzzafar et al.was reasonable to quantify CRT in samples that exceeded the
upper limit by an appropriate dilution.
3.2.3. Precision and accuracy back calculated concentrations
The intra-day and inter-day precision and accuracy for the
tested concentrations (LLQC, LQC, M1QC, M2QC and
HQC) were within acceptable limits, (Table1). Intra-day preci-
sion (expressed as percent relative standard deviation, % RSD)
ranged from 1.53% to 4.19% and the inter-day precision ran-
ged from 1.05% to 4.73%. The precision values were found to
be within the accepted limits, which indicated that the method
was reproducible. Intra and inter-day accuracy ranged fromPlease cite this article in press as: Ameeduzzafar, et al., Development and v
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99.57 ± 1.88 %, respectively, and found to be within the ac-
cepted limits. This indicated that the method was accurate
and reliable.
3.2.4. Extraction recovery and matrix effect
Extraction recovery and matrix effect were determined as de-
scribed in Section 2.5.4 and the data are shown in Table 2.
The extraction recovery of the compound from CRT matrix
was 93.98 ± 3.34 to 95.90 ± 2.64 % at LQC, M1QC,
M2QC and HQC concentrations. As for ionisation, the
peak areas of CRT after spiking evaporated aqueous humouralidation of UPLC/ESI-Q-TOF-MS for carteolol in aqueous humour:
formulation. Arabian Journal of Chemistry (2013), http://dx.doi.org/
Table 2 Extraction recovery, matrix effect (n= 6).
Conc.
(ng/mL)
Recovery
(Mean ± SD)
(%)
Matrix eﬀect
(Mean ± SD)
(%)
% RSD
2.900 (LQC) 94.43 ± 6.67 95.34 ± 7.86 3.68
34.059 (M1QC) 93.98 ± 3.34 96.12 ± 5.56 3.98
400.000 (M2QC 95.90 ± 2.64 96.72 ± 4.78 2.67
800.000 (HQC) 95.32 ± 3.98 97.54 ± 3.57 2.34
Development and validation of UPLC/ESI-Q-TOF-MS for carteolol in aqueous humour 7samples at four (LQC, M1QC, M2QC and HQC concentrations)
concentration levels were comparable to neat standard solutions
(ranged from 95.34 ± 7.86 % to 97.54 ± 3.57%), suggesting
that there was no measurable matrix effect interfered with
CRT determination in rabbit aqueous humour sample.
3.2.5. Stability study
The stability of spiked aqueous humour sample was done at
different storage conditions such as short term, long-term,
freeze–thaw, and post processing stability. The study was per-
formed at two QC levels i.e. LQC and HQC. The results were
found to be that CRT was stable during all storage condition
and data shown in Table Table 3. The recovery of the analytes
relative to that at time zero was reviewed. After short term for
24 h storage the recovery of CRT was 99.31% at LQC and
98.79% at HQC. After 1 month of storage (Long-term stabil-
ity) the recovery of CRT was 97.95 % at LQC, and 97.87%
HQC. After 1, 2 and 3 cycles of freeze–thaw (freeze–thaw sta-
bility), the average recovery of CRT was 98.63 % at LQC and
97.61% at HQC. The recovery (post processing stability) of
CRT was 98.97% at LQC and 98.64% (HQC). The above re-
sults showed that a sensitive, reproducible and robust method
for the analysis of CRT in aqueous humour had been devel-
oped and validated.
3.3. Stress degradation
3.3.1. Studies under acidic and basic conditions
After 6 h exposure in 5 N HCl and 5 ml of 5 N NaOH at
90 C, additional mass peak was observed, which revealed
the degradation of the drug. The peak observed in mass chro-
matogram is m/z 149.002 for acid degradation (Fig. 4A) and
m/z 128.9315, 231.9315, and 245.073 for base degradationTable 3 Summary of stability assessment (n= 6).
Conc. (ng/ml) Stability
LQC (2.900 ng/mL) Initial (0 h) Initial (0 h)
Short-term stability (25 C, 24 h)
Long-term stability (80 C, 30 days)
Three cycles freeze–thaw stability (thre
Post-preparative stability (10 C, 24 h)
HQC (800.0 ng/mL) Initial (0 h)
Short-term stability (25 C, 24 h)
Long-term stability (80 C, 30 days)
Three cycles freeze–thaw stability (thre
Post-preparative stability (10 C, 24 h)
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10.1016/j.arabjc.2013.11.034shown in (Fig. 4B). These masses were not observed in stan-
dard mass chromatogram shown in Fig 2A. In acid stress study
the parent peak m/z 293.1372, and daughter ion peak m/z
273.0615 are present but in base stress studies, these peaks
were absent, it showed the CRT is highly sensitive to base as
compared to acid.
3.3.2. Oxidative stress studies
After exposure in 30%v/v H2O2 in a water bath for 6 h, one
additional mass peak at m/z 128.9315 was observed but its
intensity was less as compared to parent and daughter ion peak
(m/z, 293.1372, 237.0615) (Fig. 4C). This revealed that the
drug possesses lower sensitivity to oxidative stress.
3.3.3. Photochemical stress study
The photochemical stability of the drug was also studied by
exposing the stock solution to UV light for 24 h. There was
no additional mass peak observed. The mass chromatogram
was similar to standard mass chromatogram (Fig. 4D). There-
fore the CRT is insensitive to UV light.
3.4. Preparation and characterisation of CRT nanoparticles
The preparation of CRT loaded chitosan (CS) nanoparticles
was based on the ionic inter-action of a positively charged
CS-CRT solution and negatively charged TPP solution (Calvo
et al., 1997b). The charge density of both CS and TPP solution
has a great effect on the ionic interaction. It is well known that
the charge density is greatly inﬂuenced by the pH value of solu-
tion. The nanoparticles were characterised as particle size, zeta
potential, PDI, assay of the drug and morphology by TEM.
The particle size (Fig. 5A), zeta potential, PDI and entrapment
efﬁciency of optimised formulation were 169.9 ± 3.32 nm,
34.23 ± 1.21 mV, 0.31 ± 0.04 and 70.34 ± 1.54% respec-
tively. The morphology of nanoparticles was spherical in shape
(Fig. 5B).
3.5. Pharmacokinetic study
The validated UPLC–MS/MS analytical method was success-
fully used to quantify CRT from drug solution and CRT-
nanoparticles in aqueous humour of rabbit. The high sensitiv-
ity of the present method allowed to measure aqueous humourMean ± SD
(ng/ml)
% Drug
remaining
% RSD
2.92 ± 0.02 100 0.68
2.90 ± 0.03 99.31 1.03
2.86 ± 0.02 97.95 0.70
e cycles, 20 C to 25 C) 2.88 ± 0.03 98.63 1.04
2.89 ± 0.01 98.97 0.34
795.49 ± 12.71 100 1.59
785.87 ± 8.54 98.79 1.09
778.54 ± 6.32 97.87 0.81
e cycles, 20 C to 25 C) 776.45 ± 10.26 97.61 1.32
784.74 ± 6.43 98.64 0.82
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Figure 4 Typical mass chromatogram of stress degradation study: acid degradation (A), base degradation (B), H2O2 degradation (C)
and UV degradation (D).
8 Ameeduzzafar et al.concentrations up to 24 h post dosing. The formulations (CRT
– solution and CRT – nanoparticles, dose: 1% w/v; 50 lL)
were instilled topically to New Zealand rabbit’s eye and the
developed UPLC–MS/MS method was applied to determine
their in vivo pharmacokinetics at predetermined time intervals.
Fig. 5 shows the aqueous humour concentration – time proﬁles
of carteolol after instillation. The pharmacokinetic parameters
in aqueous humour such as AUC0t, AUC01, Cmax, Tmax,
and t1/2 obtained from the pooled concentration- time, data
are shown in Table 3. The group was treated with the solution,
the drug was undetectable in aqueous humour after 6 h, due to
rapid precorneal drainage of solutions. In contrast, in the
group treated with CRT – nanoparticles the drug was detected
in aqueous humour for at least 24 h (27.21 ± 3.35 ng/mL).
The increased t1/2 value of CRT – nanoparticles (4.72 h) indi-
cated its sustained release ability. The AUC0t applied by CRT
– nanoparticle formulation (AUC0t: 5265.18 ± 25.76 ng/mL.
h) was 5.61 times higher, compared with CRT-solution
(AUC0t 939.24 ± 19.23 ng/mL). It could also be seen that
maximum level (Cmax) of carteolol in aqueous humour of
CRT –nanoparticles was approximately 2.1-fold (581.76 ±
7.52 ng/mL) higher than CRT-Solution (312.54 ± 5.34 ng/
mL). It is due to the positively charged mucoadhesive nano-
particles which interact with negatively charged cornea and
prolonged ocular contact time, thus maintaining prolonged
corneal drug concentration gradient because of chitosan hav-Please cite this article in press as: Ameeduzzafar, et al., Development and v
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10.1016/j.arabjc.2013.11.034ing bioadhesive property. The results also indicated that the
chitosan nanoparticles are able to deliver optimum levels of
drug into aqueous humour and show promise for ocular deliv-
ery for management of glaucoma. (See Fig. 6 and Table 4).4. Conclusion
This paper describes the stability indicating method develop-
ment, validation and application of a UPLC–MS/MS method
for the quantitative analysis of CRT from CRT-solution and
CRT – nanoparticle in rabbit aqueous humour. The extraction
of CRT was done by a fast liquid–liquid extraction method.
The method was proven to be highly sensitive, accurate and
selective, making it suitable for high-throughput quantitative
analysis of CRT with short run time. The drug was found to
be stable in acid, oxidative and photolytic (UV-light) condi-
tions and well degraded in basic medium. The pharmacoki-
netic parameters of nanoparticles in aqueous humour were
found to be AUC0t, (5265.18 ± 25.76 ng/mL. h) Cmax,
(581.76 ± 7.52 ng/mL), and t1/2, (4.72 h) when compared to
the drug solution. The high concentration of drug was retained
in aqueous humour for a longer period of time due to the in-
creased corneal retention when compared to drug solution.
So it has been successfully applied in pre-clinical ocular phar-
macokinetic of novel ophthalmic formulations.alidation of UPLC/ESI-Q-TOF-MS for carteolol in aqueous humour:
formulation. Arabian Journal of Chemistry (2013), http://dx.doi.org/
Figure 5 (A) Graph showing particle size distribution of
optimised nanosuspension and (B) Transmission electron micro-
graph of optimised nanosuspension.
Figure 6 Aqueous humour concentration–time proﬁles for
CRT-solution (1%w/v) and CRT–Nanoparticles (1%w/v) after
single administration.
Table 4 Pharmacokinetic parameter of carteolol solution and
carteolol nanoparticles of topical application in rabbit eyes.
Pharmacokinetic parameter CRT-solution CRT-nanoparticles
Cmax (ng/mL) 312.54 ± 5.34 581.76 ± 7.52
Tmax (h) 1.00 ± 0.12 2.00 ± 0.16
T1/2 (h) 2.52 ± 0.23 4.72 ± 0.30
AUC0t (ng/mL. h) 939.24 ± 19.23 5265.18 ± 25.76
AUC01 (ng/mL. h) 964.46 ± 24.83 5517.78 ± 30.56
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